SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 29, 2007
ADVANCED CELL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-50295 |
|
87-0656515 |
(State or other
jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
|
|
|
|
|
1201 Harbor Bay Parkway, Alameda, California 94502 |
||||
(Address of principal executive offices, including zip code) |
||||
|
||||
(510) 748-4900 |
||||
(Registrants telephone number, including area code) |
||||
|
||||
(Former name or former address, if changed since last report) |
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c)) |
ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer.
Effective as of October 29, 2007, the Companys Chief Development Officer, Pedro Huertas, M.D., Ph.D., resigned in that capacity and voluntarily terminated his employment arrangement with the Company.
Effective as of November 1, 2007, Jonathan H. Dinsmore, Ph.D., the Companys Vice President and General Manager, was promoted by the Company to the position of Senior Vice President Regulatory and Clinical.
Effective as of November 1, 2007, Ivan Wolkind ,the Companys Vice President of Finance and Chief Accounting Officer, was appointed Senior Vice President of Finance and Administration. Mr. Wolkind will continue to serve as Chief Accounting Officer.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ADVANCED CELL TECHNOLOGY, INC. |
||
|
|
|
||
|
|
|
||
|
|
By: |
/s/ William M. Caldwell, IV |
|
|
|
|
William M. Caldwell, IV |
|
|
|
|
Chief Executive Officer |
|
|
|
|
||
Dated: November 1, 2007 |
|
|
3